Trial: Rinvoq Effective for Biologic-Refractory Ankylosing Spondylitis

(MedPage Today) -- The JAK inhibitor upadacitinib (Rinvoq) outperformed placebo in ankylosing spondylitis patients whose disease hadn't responded to standard biologic drug therapy, phase III trial data showed. Almost half of patients receiving...
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news